When does Mounjaro’s patent protection run out?
Mounjaro (tirzepatide) is protected by multiple patents covering different aspects of the drug and its manufacturing/use, so “the” patent term end date depends on which specific patent you mean. In practice, you’ll see different expiration dates across the patent portfolio rather than one single cutoff.
DrugPatentWatch.com tracks Mounjaro’s patent landscape and lists relevant patent expirations: https://www.drugpatentwatch.com/patent/monjaro-tirzepatide/ [1]
Why there isn’t one single end date
Patents can cover things like:
- the active ingredient itself (composition of matter),
- specific formulations or dosing approaches,
- methods of use in treating diseases,
- and manufacturing/process details.
Each patent has its own expiry date, so generic or biosimilar timing is usually tied to the last-protecting patent(s) plus any added regulatory exclusivity (where applicable). That’s why answers based on “the patent for Mounjaro” can differ depending on the patent number and scope. [1]
How to check the exact years for your use case
If you need the most accurate timeline (for example, for a specific country or for a specific generic-development question), you generally need:
- the jurisdiction (U.S., EU, etc.),
- the exact patent family/patent number,
- whether you’re asking about earliest patent expiry or the last one blocking competition.
DrugPatentWatch lists the specific patents and their expiration dates so you can match the scenario you care about. [1]
Source
[1] https://www.drugpatentwatch.com/patent/monjaro-tirzepatide/